Preoperative high levels of serum vascular endothelial growth factor are a prognostic marker for poor outcome after surgical treatment of renal cell carcinoma

References

• Jagdev SP, Gregory W, Vasudev NS, Harnden P, Sim S, Thompson D, et al. Improving the accuracy of pre-operative survival prediction in renal cell carcinoma with C-reactive protein. Br J Cancer 2010;103:1649–56.
   PubMed Web of Science ®Google Scholar
• Ljungberg B, Campbell SC, Cho HY, Jacqmin D, Lee JE, Weikert S, et al. The epidemiology of renal cell carcinoma. Eur Urol 2011;60:615–21.
   PubMed Web of Science ®Google Scholar
• Larsen IK. Cancer Registry of Norway. Cancer in Norway 2012 – cancer incidence, mortality, survival and prevalence in Norway. Oslo: Cancer Registry of Norway; 2014.
   Google Scholar
• Småstuen M, Johannesen T, Møller B, Bray F. Long-term cancer survival: patterns and trends in Norway 1965–2007. Oslo: Cancer Registry of Norway; 2008.
   Google Scholar
• Finley DS, Pantuck AJ, Belldegrun AS. Tumor biology and prognostic factors in renal cell carcinoma. Oncologist 2011;16:4–13.
   PubMed Web of Science ®Google Scholar
• Ferrara N. Vascular endothelial growth factor. Arterioscler Thromb Vasc Biol 2009;29:789–91.
   PubMed Web of Science ®Google Scholar
• Grünewald FS, Prota AE, Giese A, Ballmer-Hofer K. Structure–function analysis of VEGF receptor activation and the role of coreceptors in angiogenic signaling. Biochim Biophys Acta 2010;1804:567–80.
   PubMed Web of Science ®Google Scholar
• Simons M. An inside view: VEGF receptor trafficking and signaling. Physiology (Bethesda) 2012;27:213–22.
   PubMed Web of Science ®Google Scholar
• Rioux-Leclercq N, Fergelot P, Zerrouki S, Leray E, Jouan F, Bellaud P, et al. Plasma level and tissue expression of vascular endothelial growth factor in renal cell carcinoma: a prospective study of 50 cases. Hum Pathol 2007;38:1489–95.
   PubMed Web of Science ®Google Scholar
• Ferrara N. Vascular endothelial growth factor as a target for anticancer therapy. Oncologist 2004;9:2–10.
   PubMed Web of Science ®Google Scholar
• Schips L, Dalpiaz O, Lipsky K, Langner C, Rehak P, Puerstner P, et al. Serum levels of vascular endothelial growth factor (VEGF) and endostatin in renal cell carcinoma patients compared to a control group. Eur Urol 2007;51:168–74.
   PubMed Web of Science ®Google Scholar
• Welti J, Loges S, Dimmeler S, Carmeliet P. Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer. J Clin Invest 2013;123:3190–200.
   PubMed Web of Science ®Google Scholar
• Dosquet C, Coudert MC, Lepage E, Cabane J, Richard F. Are angiogenic factors, cytokines, and soluble adhesion molecules prognostic factors in patients with renal cell carcinoma? Clin Cancer Res 1997;3:2451–8.
   PubMed Web of Science ®Google Scholar
• George S, Bukowski RM. Biomarkers in clear cell renal cell carcinoma. Expert Rev Anticancer Ther 2007;7:1737–47.
   PubMed Web of Science ®Google Scholar
• Beisland C, Hjelle KM, Reisæter LAR, Bostad L. Observation should be considered as an alternative in management of renal masses in older and comorbid patients. Eur Urol 2009;55:1419–29.
   PubMed Web of Science ®Google Scholar
• Sun M, Bianchi M, Trinh Q-D, Hansen J, Abdollah F, Hanna N, et al. Comparison of partial vs radical nephrectomy with regard to other-cause mortality in T1 renal cell carcinoma among patients aged ≥75 years with multiple comorbidities. BJU Int 2013;111:67–73.
   PubMed Web of Science ®Google Scholar
• Greene FL, Sobin LH. A worldwide approach to the TNM staging system: collaborative efforts of the AJCC and UICC. J Surg Oncol 2009;99:269–72.
   PubMed Web of Science ®Google Scholar
• Fuhrman SA LL, Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Pathol 1982;6:655–63.
   Web of Science ®Google Scholar
• Cox DR. Regression models and life tables (with discussion). J R Stat Soc B 1972;34:187–220.
   Google Scholar
• Jacobsen JAN, Rasmuson T, Grankvist K, Ljungberg B. Vascular endothelial growth factor as prognostic factor in renal cell carcinoma. J Urol 2000;163:343–7.
   PubMed Web of Science ®Google Scholar
• Fujita N, Okegawa T, Tambo M, Shishido T, Nutahara K, Higashihara E. [Predicting postoperative recurrence of renal cell carcinoma using serum vascular endothelial growth factor]. Nihon Hinyokika Gakkai Zasshi 2013;104:1–5.
   PubMedGoogle Scholar
• Negrier S, Perol D, Menetrier-Caux C, Escudier B, Pallardy M, Ravaud A, et al. Interleukin-6, interleukin-10, and vascular endothelial growth factor in metastatic renal cell carcinoma: prognostic value of interleukin-6 – from the Groupe Français d’Immunothérapie. J Clin Oncol 2004;22:2371–8.
   PubMed Web of Science ®Google Scholar
• Polimeno M, Napolitano M, Costantini S, Portella L, Esposito A, Capone F, et al. Regulatory T cells, interleukin (IL)-6, IL-8, vascular endothelial growth factor (VEGF), CXCL10, CXCL11, epidermal growth factor (EGF) and hepatocyte growth factor (HGF) as surrogate markers of host immunity in patients with renal cell carcinoma. BJU Int 2013;112:686–96.
   PubMed Web of Science ®Google Scholar
• Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Staehler M, et al. Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III Treatment Approaches in Renal Cancer Global Evaluation Trial. J Clin Oncol 2009;27:3312–18.
   PubMed Web of Science ®Google Scholar
• Kim JJ, Vaziri SAJ, Rini BI, Elson P, Garcia JA, Wirka R, et al. Association of VEGF and VEGFR2 single nucleotide polymorphisms with hypertension and clinical outcome in metastatic clear cell renal cell carcinoma patients treated with sunitinib. Cancer 2012;118:1946–54.
   PubMed Web of Science ®Google Scholar
• Sand KE, Hjelle KM, Rogde ÅJ, Gudbrandsdottir G, Bostad L, Beisland C. Incidentally detected renal cell carcinomas are highly associated with comorbidity and mortality unrelated to renal cell carcinoma. Scand J Urol 2013;47:462–71.
   PubMed Web of Science ®Google Scholar
• Guðmundsson E, Hellborg H, Lundstam S, Erikson S, Ljungberg B. Metastatic potential in renal cell carcinomas ≤7 cm: Swedish Kidney Cancer Quality Register data. Eur Urol 2011;60:975–82.
   PubMed Web of Science ®Google Scholar
• Sciarra A, Cattarino S, Salciccia S, Alfarone A, Gentilucci A, Parente U, et al. The emerging role of targeted therapy in renal cell carcinoma (RCC): is it time for a neoadjuvant or an adjuvant approach? Crit Rev Oncol Hematol 2012;81:151–62.
   PubMed Web of Science ®Google Scholar